CD274 and neoplasm: Predictors for an anti-tumor response to ICIs currently are: high PD-L1 expression; microsatellite instable cancers or microsatellite high (MSI-H) cancers; tumor infiltrating lymphocytes (TILs) at the edge of the tumor and high mutational burden (TMB).